Satoris Inc

Satoris is a privately held company founded in 2003 with the mission of developing and commercializing diagnostic technologies for molecular profiling of neurological disorders. The first proprietary tests under development by Satoris target Alzheimer’s disease (AD). There are currently over 5.3 million AD patients in the US and over 26 million worldwide and these numbers are expected to quadruple by 2050 unless more effective treatments emerge. The core discovery of classification and prediction of clinical Alzheimer’s diagnostics based on plasma signaling proteins was published as a landmark study in Nature Medicine. Satoris is applying and validating panels of these proteins, in combination with proprietary decision-based algorithms, onto a number of laboratory test platforms. Satoris’ future product pipeline will include tests for the efficient and early diagnosis of a range of neurological disorders. Our tools will be designed to optimize patient management and therapy thereby reducing healthcare costs. To understand these complex biological pathways our products may also include complex algorithms, databases, and other bioinformatics tools developed in conjunction with leading centers. These biomarker protein assays will enable disease progression studies possible that were not even imaginable just a few years ago and will enable studies to characterize the early detection, treatment, and management of the disease and the clinical applications as a diagnostic. It is expected that with further validation, Satoris tests will enable early detection and diagnosis of AD, leading to more effective and efficient patient management.